Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chimeric Antigen Receptor T‑Cell Therapy Targeting Tumor Necrosis Factor Receptor Superfamily Member 8 (CD30) for Relapsed or Refractory Anaplastic Large Cell Lymphoma: Rationale, Strategies, and Emerging Clinical Evidence.

ACS pharmacology & translational science·2026
Same author

Pragmatic defence of the register system: strengthening Clarke's consequentialist case for managing conscientious objection.

Journal of medical ethics·2026
Same author

Emerging therapeutic strategies for CD30-positive lymphomas.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2025
Same author

Beyond instrumental rationality: a thicker account of intention in double-effect sedation.

Journal of medical ethics·2025
Same author

Designing inclusive digital twins: ethical and practical considerations for trans healthcare.

Journal of medical ethics·2025
Same author

Constructing Risk Ethically: A Normative Extension of Clark et al.'s "Risk-Making" Theory for Disorders of Consciousness.

AJOB neuroscience·2025
Same journal

Oral Delivery of Tocotrienols: Addressing Pharmacokinetic Challenges With Formulation-Based Strategies.

Lipids·2026
Same journal

Exometabolomics Reveals Metabolic Modulation Induced by Chia Oil Supplementation in Adipose Tissue Explants From Obese Mice.

Lipids·2026
Same journal

Analysis of the Value of Combined Detection of Serum miR-302a-3p and Low Density Lipoprotein Cholesterol in the Diagnosis of Coronary Heart Disease.

Lipids·2026
Same journal

Association Between C-Reactive Protein-Triglyceride Glucose Index, and the Risk of Osteoarthritis and Rheumatoid Arthritis: Results From NHANES 1999-2010.

Lipids·2026
Same journal

Transcriptomic Analysis of Shared Lipid Metabolism in Chronic Hepatitis B and Non-Alcoholic Fatty Liver Disease Using Weighted Gene Expression Network Analysis.

Lipids·2026
Same journal

Lipid-Soluble Signaling Molecular Model Predicts Prognosis and Immunotherapy Response in Gastric Cancer.

Lipids·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

Very Low Cholesterol Non-Cardiovascular Risks: A Critical Appraisal and Framework for Individualized Management.

Alberto Boretti1

  • 1Independent Scientist, Wellington, New Zealand.

Lipids
|June 15, 2026
PubMed
Summary
This summary is machine-generated.

Lowering LDL-C significantly reduces cardiovascular disease. While observational studies suggest risks at very low cholesterol, randomized trials and Mendelian randomization do not confirm causal links to adverse non-cardiovascular outcomes.

Keywords:
LDL‐Cadult populationcardiovascular preventioncholesterolfrailtymathematical modelingmortalitypersonalized medicinereverse causationstatins

Related Experiment Videos

Last Updated: Jun 16, 2026

Assessing Whole-Body Lipid-Handling Capacity in Mice
07:57

Assessing Whole-Body Lipid-Handling Capacity in Mice

Published on: November 24, 2020

Area of Science:

  • Cardiology
  • Clinical Lipidology
  • Translational Medicine

Background:

  • Randomized trials confirm LDL-C reduction benefits for atherosclerotic cardiovascular disease.
  • Observational studies suggest U-shaped cholesterol-mortality associations, raising concerns about potential non-cardiovascular risks at very low LDL-C levels (<70 mg/dL).
  • Distinguishing observational associations from causal evidence is crucial for clinical decision-making.

Purpose of the Study:

  • To critically evaluate the evidence linking very low LDL-C to non-cardiovascular outcomes.
  • To differentiate observational correlations from proven causal relationships.
  • To inform personalized patient management strategies regarding LDL-C targets.

Main Methods:

  • Narrative review of existing literature, distinguishing observational data from randomized controlled trial (RCT) and Mendelian randomization (MR) evidence.
  • Definition of "very low cholesterol" as LDL-C < 70 mg/dL.
  • Inclusion of conceptual mathematical models for illustration, not clinical validation.

Main Results:

  • Observational studies correlate low cholesterol with cancer, depression, hemorrhagic stroke, and infection, but these are susceptible to reverse causation.
  • RCTs and MR studies have not established causal links between pharmacologically induced low LDL-C and these adverse outcomes.
  • Conceptual mathematical models are presented for hypothesis generation, not clinical prediction.

Conclusions:

  • For most high-risk patients, the cardiovascular benefits of lowering LDL-C outweigh theoretical non-cardiovascular risks.
  • Individualized assessment is warranted for specific subgroups (e.g., very elderly, frail, prior hemorrhagic stroke).
  • Observational data should reinforce, not challenge, established LDL-C reduction benefits, emphasizing context-driven personalization.